In the fields of targeted biopharmaceuticals, precision diagnostics, and basic immunology research, antibody discovery represents a core step in the development of antibody drugs and diagnostic reagents. Compared with traditional hybridoma-based antibody screening technologies, the phage display platform has become a mainstream core technology system for antibody discovery, offering significant advantages such as high throughput, high efficiency, and no species limitation. This platform leverages large-scale naïve and immune phage display antibody libraries to enable rapid screening and enrichment of specific antibodies, efficiently obtaining high-affinity candidate antibody genes, and effectively overcoming challenges associated with traditional hybridoma technologies, including long screening cycles and difficulties in antibody engineering.
As the most widely used recombinant small-molecule antibody, the single-chain variable fragment (scFv) is composed of the variable regions of the antibody heavy and light chains joined by a linker peptide. It offers unique advantages including small molecular size, enhanced tissue penetration, low immunogenicity, and ease of genetic modification and scalable production. Leveraging our well-established phage display platform, we have built a standardized scFv expression platform capable of delivering end-to-end services encompassing gene optimization, vector construction, protein expression, purification, and activity validation—supporting your research every step of the way.
Leveraging our well-established phage display platform, KMD Bioscience not only provides construction services for various types of scFv antibody libraries—including immune, naïve, and synthetic libraries—but also enables the production of high-affinity, structurally stable scFv antibodies. With years of experience in recombinant antibody expression, we have established a multi-platform system encompassing mammalian cells (CHO/HEK293), E. coli, baculovirus-insect cell systems, and yeast, enabling efficient soluble expression and high-purity preparation of scFv antibodies. Furthermore, we have extended our service chain to comprehensive characterization and functional validation of scFv antibodies, with rigorous quality control of antibody affinity, specificity, and stability. This truly delivers end-to-end technical services for scFv antibody expression, providing efficient and reliable support for both research and drug development.
0
